#######################
# Document Properties #
#######################
SET DOCUMENT Copyright   = "Copyright Â© 2019 Fraunhofer Institute SCAI, All rights reserved."
SET DOCUMENT Licenses    = "CC BY 4.0"
SET DOCUMENT ContactInfo = "charles.hoyt@scai.fraunhofer.de"

SET DOCUMENT Name        = "The interrelationship between mitochondrial dysfunction and transcriptional dysregulation in Huntington disease."
SET DOCUMENT Version     = "1.0.0"
SET DOCUMENT Authors     = "Yojana Gadiya"
SET DOCUMENT Description = ""

##############
# Namespaces #
##############

# Namespaces hosted on https://github.com/pharmacome/conso
# --------------------------------------------------------
 DEFINE NAMESPACE CHEBI          AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/chebi-names.belns"
 DEFINE NAMESPACE CONSO          AS URL "https://raw.githubusercontent.com/pharmacome/conso/3c93a65dc48e6786fe29ae55aa36cf9a902fe8c6/export/conso-names.belns"
# DEFINE NAMESPACE DRUGBANK       AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/drugbank-names.belns"
 DEFINE NAMESPACE DOID           AS URL "https://raw.githubusercontent.com/pharmacome/conso/c0c576e3d3ab9b25a3982251a4ee2fd7c49e1679/external/doid-names.belns"
# DEFINE NAMESPACE ECCODE         AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/ec-code.belns"
 DEFINE NAMESPACE EFO            AS URL "https://raw.githubusercontent.com/pharmacome/conso/5d2c2ea6f7112421cc8089a3f021a75ab60bb373/external/efo-names.belns"
 DEFINE NAMESPACE FB             AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/fb-names.belns"
DEFINE NAMESPACE HGNC           AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc-names.belns"
 DEFINE NAMESPACE HGNCGENEFAMILY AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc.genefamily-names.belns"
 DEFINE NAMESPACE HP             AS URL "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/hp-names.belns"
 DEFINE NAMESPACE GO             AS URL "https://raw.githubusercontent.com/pharmacome/conso/d9d270e11aac480542c412d4222983a5f042b8ae/external/go-names.belns"
# DEFINE NAMESPACE INTERPRO       AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/interpro-names.belns"
 DEFINE NAMESPACE MESH           AS URL "https://raw.githubusercontent.com/pharmacome/conso/f02c6ad4a4791a8ed45448513b9de8c8f1b00c87/external/mesh-names.belns"
# DEFINE NAMESPACE MGI            AS URL "https://raw.githubusercontent.com/pharmacome/conso/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/mgi-names.belns"
# DEFINE NAMESPACE MIRBASE        AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/mirbase-names.belns"
# DEFINE NAMESPACE NCBIGENE       AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/ncbigene.belns"
# DEFINE NAMESPACE PFAM           AS URL "https://raw.githubusercontent.com/pharmacome/conso/c328ad964c08967a0417a887510b97b965a62fa5/external/pfam-names.belns"
# DEFINE NAMESPACE RGD            AS URL "https://raw.githubusercontent.com/pharmacome/conso/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/rgd-names.belns"

# Namespaces hosted on https://github.com/sorgerlab/famplex
# ---------------------------------------------------------
# DEFINE NAMESPACE FPLX           AS URL "https://raw.githubusercontent.com/sorgerlab/famplex/d9ec0526c20795146a9a6aef17496efe1a36cac6/export/famplex.belns"

# Namespaces defined with regular expressions
# -------------------------------------------
# DEFINE NAMESPACE DBSNP          AS PATTERN "rs[0-9]+"
# DEFINE NAMESPACE TAXONOMY       AS PATTERN "^\d+$"
# DEFINE NAMESPACE UNIPROT        AS PATTERN "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\.\d+)?$"
 DEFINE NAMESPACE PUBCHEM        AS PATTERN "^\d+$"
 DEFINE NAMESPACE MP             AS PATTERN "^\d{7}$"
###############
# Annotations #
###############

# Annotations defined with regular expressions
# --------------------------------------------
DEFINE ANNOTATION Species       AS PATTERN "^\d+$"

# Annotations hosted on https://arty.scai.fraunhofer.de/artifactory/bel/annotation
# --------------------------------------------------------------------------------
# DEFINE ANNOTATION Anatomy       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno"
# DEFINE ANNOTATION CellLine      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno"
# DEFINE ANNOTATION CellStructure AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno"
# DEFINE ANNOTATION Cell          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno"
# DEFINE ANNOTATION Confidence    AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
# DEFINE ANNOTATION Disease       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno"
# DEFINE ANNOTATION Gender        AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno"
 DEFINE ANNOTATION MeSHAnatomy   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
 DEFINE ANNOTATION MeSHDisease   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
# DEFINE ANNOTATION Subgraph      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno"
# DEFINE ANNOTATION TextLocation  AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"

##############
# Statements #
##############
SET Citation = {"PubMed", "20556492"}

SET MeSHDisease = "Huntington Disease"
#similar results in R6/2 line mice
SET Species = "10090"


SET Evidence = "For example, positron emission tomography (PET) scans that utilize 18F-2-
deoxyglucose (18F-2-DOG) showed a significant reduction in glucose uptake in cortex and
striatum of HD patients even prior to striatal neuronal loss and pathological symptoms (Gil
and Rego 2008)."
SET MeSHAnatomy = {"Neocortex","Neostriatum"}
path(DOID:"Huntington's disease") -| bp(GO:"glucose import")

SET Evidence = "Paradoxical increases in lactate have been observed in the cortex of
symptomatic HD patients and in the striatum of presymptomatic HD patients using 1Hmagnetic
resonance spectroscopy (MRS) (Jenkins et al. 1998)."
path(DOID:"Huntington's disease") -> a(CHEBI:lactate)
UNSET MeSHAnatomy

SET Evidence = "In addition, functional defects have been observed. For example, deficits in
succinate dehydrogenase activity, a component of complex II of ETC as well as the TCA
cycle, were observed in postmortem HD brains in 1974 (Stahl and Swanson 1974)."
#along with mitochondrial morphological defects
SET MeSHAnatomy = "Brain"
path(DOID:"Huntington's disease") neg bp(GO:"regulation of succinate dehydrogenase activity")
path(DOID:"Huntington's disease") neg bp(GO:"tricarboxylic acid cycle")
UNSET MeSHAnatomy

SET Evidence = "Reduced
expression of complex II subunits has been observed in striatum of HD patients (Benchoua
et al. 2006)."
SET MeSHAnatomy = "Neostriatum"
path(DOID:"Huntington's disease") -| p(HGNCGENEFAMILY:"Mitochondrial complex II: succinate dehydrogenase subunits")
UNSET MeSHAnatomy

SET Evidence = "The activities of complex III in the caudate and putamen and complex IV in the
putamen are also significantly decreased in HD cases (Gil and Rego 2008)."
SET MeSHAnatomy = {"Putamen","Caudate Nucleus"}
path(DOID:"Huntington's disease") -| act(p(HGNCGENEFAMILY:"Mitochondrial complex III: ubiquinol-cytochrome c reductase complex subunits"))
UNSET MeSHAnatomy
SET MeSHAnatomy = "Putamen"
path(DOID:"Huntington's disease") -| act(p(HGNCGENEFAMILY:"Mitochondrial complex IV: cytochrome c oxidase subunits"))
UNSET MeSHAnatomy

SET Evidence = "The activity of
aconitase, an essential enzyme in the TCA cycle, has been reported to be significantly
decreased in the striatum and cerebral cortex (Tabrizi et al. 2000), and loss of the pyruvate
dehydrogenase complex was observed in symptomatic patients with caudate/putamen
atrophy (Butterworth et al. 1985; Sorbi et al. 1983)."
SET MeSHAnatomy = {"Neocortex","Neostriatum"}
path(HP:"Caudate atrophy") -| act(p(HGNC:ACO2))
UNSET MeSHAnatomy
path(HP:"Caudate atrophy") neg p(HGNCGENEFAMILY:"Pyruvate dehydrogenase complex")

SET Evidence = "Concurrent with these changes in
mitochondrial morphology and function, there is a significant decrease in mitochondrial
DNA in the cerebral cortex of HD patients (Horton et al. 1995)."
SET MeSHAnatomy = "Cerebral Cortex"
path(DOID:"Huntington's disease") -| a(EFO:"mitochondrial DNA")
UNSET MeSHAnatomy

SET Evidence = "31P-MRS showed significantly reduced ATP production in muscle of presymptomatic and symptomatic HD patients (Lodi et al. 2000)."
SET MeSHAnatomy = "Muscles"
path(DOID:"Huntington's disease") -| bp(GO:"ATP biosynthetic process")
UNSET MeSHAnatomy

SET Evidence = "Other groups
found out abnormal morphologies as well as decreased membrane potential in mitochondria
from peripheral tissues including lymphoblasts and muscle of HD patients (Panov et al.
2002; Squitieri et al. 2006, 2010)."
SET MeSHAnatomy = {"Lymphoid Progenitor Cells","Muscles","Mitochondrial Membranes"}
path(DOID:"Huntington's disease") -| bp(GO:"regulation of membrane potential")
UNSET MeSHAnatomy

SET Evidence = "As in the brain, mitochondrial DNA in leukocytes from
HD patients was depleted (Liu et al. 2008)."
SET MeSHAnatomy = "Leukocytes"
path(DOID:"Huntington's disease") -| bp(GO:"ATP biosynthetic process")
UNSET MeSHAnatomy

SET Evidence = "A decreased stability of muscle mitochondria
against Ca2+-induced mPTP opening and an increased sensitivity of complex I-dependent
respiration against Ca2+-induced inhibition have been found in R6/2 mice, leading to
energetic deficits and muscle atrophy (Gizatullina et al. 2006)."
path(DOID:"Huntington's disease") neg bp(MESH:"Energy Metabolism")
path(DOID:"Huntington's disease") -> path(DOID:"muscular atrophy")

SET Evidence = "Panov et al. (2002) showed that mitochondria isolated from lymphoblasts of HD patients
have decreased Ca2+-buffering capacity and undergo mitochondrial membrane
depolarization at lower Ca2+ concentrations."
SET MeSHAnatomy = "Lymphoid Progenitor Cells"
path(DOID:"Huntington's disease") -| bp(GO:"calcium ion homeostasis")
SET MeSHAnatomy = "Mitochondrial Membranes"
a(CHEBI:"calcium(2+)") reg bp(GO:"membrane depolarization")
path(DOID:"Huntington's disease") -| bp(GO:"membrane depolarization")
UNSET MeSHAnatomy

SET Evidence = "Choo et al. (2004) showed that huntingtin was present in the mitochondrial fraction
purified from human neuroblastoma cells and clonal striatal cells and associated with the
outer mitochondrial membrane."
#also with clonal striatal cells
path(DOID:neuroblastoma) -> p(HGNC:HTT,pmod(CONSO:"CAG repeats"),loc(GO:"mitochondrial outer membrane"))

SET Evidence = "A recombinant truncated mHtt directly added to isolated
mouse liver mitochondria significantly decreased the Ca2+-threshold for mPTP opening, an
effect that was abolished by cyclosporin A (CsA), an mPTP inhibitor."
#mPTP - permeability transition pore
SET MeSHAnatomy = "Mitochondria, Liver"
a(CHEBI:"calcium(2+)") reg complex(GO:"mitochondrial permeability transition pore complex")
a(CHEBI:"cyclosporin A") -| complex(GO:"mitochondrial permeability transition pore complex")
UNSET MeSHAnatomy

SET Evidence = "ADP treatment attenuated the mitochondrial membrane potential defect and CsA
treatment prevented the decreases in Ca2+ uptake capacity (Milakovic et al. 2006)."
SET MeSHAnatomy = "Mitochondrial Membranes"
a(CHEBI:ADP) reg bp(GO:"regulation of membrane potential")
a(CHEBI:"cyclosporin A") -> bp(GO:"calcium import into the mitochondrion")
UNSET MeSHAnatomy

SET Evidence = "Striatal
neurons from Hdh150 knock-in mice exhibit increased susceptibility to Ca2+-deregulation
by NMDA receptor activation than striatal neurons from wild type littermates, when
pyruvate instead of glucose is used in media to emphasize Oxphos dependent bioenergetics
(Oliveira et al. 2007)."
#Hdh150 strain
SET MeSHAnatomy = "Neostriatum"
p(HGNC:HTT,pmod(CONSO:"CAG repeats")) -> act(p(HGNCGENEFAMILY:"Glutamate ionotropic receptor NMDA type subunits"))
act(p(HGNCGENEFAMILY:"Glutamate ionotropic receptor NMDA type subunits")) -- bp(GO:"calcium ion homeostasis")
UNSET MeSHAnatomy

SET Evidence = "mHtt
directly interacts with C-terminal region of the type 1 inositol 1,4,5-trisphosphate (InsP3)
receptor (InsP3R1), resulting in increased sensitivity of InsP3R1 to activation by InsP3
(Tang et al. 2003)."
#interaction with C-terminal of ITPR1
complex(p(HGNC:HTT,pmod(CONSO:"CAG repeats")),p(HGNC:ITPR1,frag("?"))) -> act(p(HGNC:ITPR1))
act(p(HGNC:ITPR1)) -> a(CHEBI:"1D-myo-inositol 1,4,5-trisphosphate")

SET Evidence = "Moreover, mHtt enhances the activity of N-methyl D-aspartate receptors
(NMDARs) harboring the NR2B subunit, resulting from increased NMDAR trafficking to
the plasma membrane (Fan et al. 2007; Sun et al. 2001; Zeron et al. 2002)."
p(HGNC:HTT,pmod(CONSO:"CAG repeats")) -> tloc(p(HGNCGENEFAMILY:"Glutamate ionotropic receptor NMDA type subunits"),fromLoc(GO:cytoplasm),toLoc(GO:"plasma membrane"))
tloc(p(HGNCGENEFAMILY:"Glutamate ionotropic receptor NMDA type subunits"),fromLoc(GO:cytoplasm),toLoc(GO:"plasma membrane")) -> act(p(HGNCGENEFAMILY:"Glutamate ionotropic receptor NMDA type subunits"))

SET Evidence = "Importantly,
MSNs express high levels of the NR2B subunit, implying a greater sensitivity to
excitotoxicity caused by NMDAR activation (Heng et al. 2009; Rigby et al. 1996)."
#MSN - medium size spiny neurons
#0008235 - increased sensitivity to excitotoxicity
act(p(HGNCGENEFAMILY:"Glutamate ionotropic receptor NMDA type subunits")) -> path(MP:0008235)
p(HGNC:GRIN2B) -> act(p(HGNCGENEFAMILY:"Glutamate ionotropic receptor NMDA type subunits"))
p(HGNC:GRIN2B) -> path(MP:0008235)

SET Evidence = "In
addition, inhibition of mPTP opening by treatment with CsA and bongkrekic acid
significantly diminished NMDA-induced Ca2+ influx and mitochondrial membrane potential
loss in MSNs of YAC128 mouse (Fernandes et al. 2007)."
a(CHEBI:"cyclosporin A") -| complex(GO:"mitochondrial permeability transition pore complex")
a(CHEBI:"bongkrekic acid") -| complex(GO:"mitochondrial permeability transition pore complex")
a(CHEBI:"cyclosporin A") -| act(p(HGNCGENEFAMILY:"Glutamate ionotropic receptor NMDA type subunits"))
a(CHEBI:"bongkrekic acid") -| act(p(HGNCGENEFAMILY:"Glutamate ionotropic receptor NMDA type subunits"))
act(p(HGNCGENEFAMILY:"Glutamate ionotropic receptor NMDA type subunits")) -> bp(GO:"calcium ion import")
a(CHEBI:"cyclosporin A") -| bp(GO:"calcium ion import")
a(CHEBI:"bongkrekic acid") -| bp(GO:"calcium ion import")
#YAC128 mouse
a(CHEBI:"cyclosporin A") reg bp(GO:"regulation of membrane potential")
a(CHEBI:"bongkrekic acid") reg bp(GO:"regulation of membrane potential")

SET Evidence = "Similarly, Htt is likely to have an
effect on the function of the voltage-gated Ca2+ channels (VGCCs), because Htt associates
with the synaptic protein interaction (synprint) region of N-type VGCC (Swayne et al. 2005)
and the Î±2/Î´ auxiliary subunit of VGCC (Kaltenbach et al. 2007), and MSNs from R6/2
mice at 3â6 weeks of age show increases in voltage-gated Ca2+ conductances (Cepeda et al.
2007)."
complex(p(HGNC:HTT,pmod(CONSO:"CAG repeats")),p(HGNCGENEFAMILY:"Calcium voltage-gated channel alpha1 subunits")) -> bp(GO:"regulation of voltage-gated calcium channel activity")
complex(p(HGNC:HTT,pmod(CONSO:"CAG repeats")),p(HGNCGENEFAMILY:"Calcium voltage-gated channel auxiliary alpha2delta subunits")) -> bp(GO:"regulation of voltage-gated calcium channel activity")

SET Evidence = "Photoreceptor neurodegeneration in an HD fly model expressing a full length of mHtt
with a polyglutamine stretch of 128 was rescued by removing one copy of Dmca1D (a Ltype
VGCC pore subunit of Drosophila) (Romero et al. 2008)."
SET Species = "7227"
SET MeSHAnatomy = "Photoreceptor Cells"
p(FB:htt,pmod(CONSO:"CAG repeats")) -> path(HP:Neurodegeneration)
p(FB:"Ca-alpha1D") -| path(HP:Neurodegeneration)
UNSET MeSHAnatomy
UNSET Species

SET Evidence = "Initial studies showed that mHtt interferes with cAMP-responsive element (CRE) binding
protein (CREB) mediated transcriptional processes through direct interaction with CBP
(CREB-binding protein) (Steffan et al. 2000) and with TATA box-binding protein (TBP)-
associated factor TAF4/ TAFII130 (Dunah et al. 2002; Shimohata et al. 2000), leading to an
increase in mHtt-induced cytotoxicity (Steffan et al. 2001)."
complex(p(HGNC:HTT,pmod(CONSO:"CAG repeats")),p(HGNC:CREBBP),p(HGNC:TAF4)) neg act(p(HGNC:CREBBP),ma(tscript))
complex(p(HGNC:HTT,pmod(CONSO:"CAG repeats")),p(HGNC:CREBBP),p(HGNC:TAF4)) -> path(MESH:"Cytotoxicity, Immunologic")
complex(p(HGNC:HTT,pmod(CONSO:"CAG repeats")),p(HGNC:CREBBP),p(HGNC:TAF4)) -> p(HGNC:HTT,pmod(CONSO:"CAG repeats"))
p(HGNC:HTT,pmod(CONSO:"CAG repeats")) -> path(MESH:"Cytotoxicity, Immunologic")

SET Evidence = "The peroxisome proliferator-activated receptor Î³ (PPARÎ³) coactivator-1Î± (PGC-1Î±) is an
orchestrator of mitochondrial function via integration of signals that regulate mitochondrial
biogenesis and respiration, detoxification of ROS, energy metabolism, and thermogenesis
(Houten and Auwerx 2004)."
p(HGNC:PPARGC1A) reg bp(MESH:"Mitochondrial Dynamics")
p(HGNC:PPARGC1A) reg bp(GO:"mitochondrion organization")
p(HGNC:PPARGC1A) reg bp(GO:"cellular respiration")
p(HGNC:PPARGC1A) -> a(CHEBI:"reactive oxygen species")
p(HGNC:PPARGC1A) reg bp(GO:detoxification)
p(HGNC:PPARGC1A) reg bp(MESH:"Energy Metabolism")
p(HGNC:PPARGC1A) reg bp(MESH:Thermogenesis)

SET Evidence = "PGC-1Î± interacts with a number of transcription factors
including PPARÎ³ of the PPAR family, which regulates adipogenesis and lipid metabolism,
and the nuclear respiratory factor-1/2 (NRF-1/2) which play a pivotal role in mitochondrial
respiration."
complex(p(HGNC:PPARGC1A),p(HGNC:NRF1),p(HGNC:PPARG)) reg bp(GO:"cellular respiration")
p(HGNC:PPARG) reg bp(GO:"lipid biosynthetic process")
p(HGNC:PPARG) reg bp(GO:"lipid metabolic process")

SET Evidence = "The expression of PGC-1Î± is repressed in both in vitro and in vivo models of
HD, at least partially due to the fact that mHtt directly interferes with the CREB/TAF4
signaling pathway which is a predominant regulator of PGC-1Î± expression (Cui et al. 2006)."
p(HGNC:HTT,pmod(CONSO:"CAG repeats")) -| r(HGNC:PPARGC1A)
complex(p(HGNC:CREBBP),p(HGNC:TAF4)) reg r(HGNC:PPARGC1A)

SET Evidence = "The reduced level of cAMP in HD mice and HD patients likely contributes to the significant
reduction in CREB activation (Gines et al. 2003)."
a(CHEBI:"3',5'-cyclic AMP") -> act(p(HGNC:CREBBP),ma(tscript))

SET Evidence = "Recent studies demonstrate
that TZDs show protective effects in models of Alzheimerâs disease (Heneka et al. 2005;
Landreth 2006), Parkinsonâs disease (Breidert et al. 2002), amyotrophic lateral sclerosis
(Kiaei et al. 2005), stroke (Luo et al. 2006), and multiple sclerosis (Niino et al. 2001)."
#thiazolidinediones (TZDs) - osiglitazone, pioglitazone, troglitazone
a(CHEBI:thiazolidinediones) -| path(DOID:"Alzheimer's disease")
a(CHEBI:thiazolidinediones) -| path(DOID:"Parkinson's disease")
a(CHEBI:thiazolidinediones) -| path(DOID:"amyotrophic lateral sclerosis")
a(CHEBI:thiazolidinediones) -| path(EFO:stroke)
a(CHEBI:thiazolidinediones) -| path(DOID:"multiple sclerosis")

SET Evidence = "More
importantly, we found out that STHdhQ111/Q111 cells exhibit significant decreases in PPARÎ³
activity, that thapsigargin induced a decrease in mitochondrial membrane potential and an
increase in ROS production only in STHdhQ111/Q111 cells, and that PPARÎ³ activation by
rosiglitazone treatment protected STHdhQ111/Q111 cells from thapsigargin-induced
mitochondrial membrane potential loss and ROS production (Quintanilla et al. 2008)."
#STHdhQ111/Q111 cells
a(CHEBI:thapsigargin) -| bp(GO:"regulation of membrane potential")
a(CHEBI:thapsigargin) -> path(HP:"Increased reactive oxygen species production")
a(CHEBI:rosiglitazone) -> p(HGNC:PPARG)
a(CHEBI:rosiglitazone) -| act(a(CHEBI:thapsigargin))
a(CHEBI:rosiglitazone) -> bp(GO:"regulation of membrane potential")
a(CHEBI:rosiglitazone) -| path(HP:"Increased reactive oxygen species production")
